Kostas Biliouris
Stock Analyst at BMO Capital
(1.12)
# 3,767
Out of 4,996 analysts
63
Total ratings
36.73%
Success rate
-16.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $18.36 | +172.33% | 9 | Sep 22, 2025 | |
| TRML Tourmaline Bio | Downgrades: Market Perform | $35 → $48 | $47.74 | +0.54% | 1 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $446.40 | +5.29% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $64.09 | +9.22% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $2.47 | +61.94% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.26 | +145.40% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $42.95 | +67.64% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $13.15 | +280.23% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.54 | +351.26% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $16.31 | +206.56% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $5.04 | +574.60% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $23.26 | +50.47% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $2.29 | +642.36% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.39 | +376.76% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $33.37 | +169.70% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $40.66 | +195.13% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $22.97 | +148.15% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $50.05 | -26.07% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $53.85 | +85.70% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $5.12 | +271.09% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $61.67 | +58.91% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $18.36
Upside: +172.33%
Tourmaline Bio
Sep 15, 2025
Downgrades: Market Perform
Price Target: $35 → $48
Current: $47.74
Upside: +0.54%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $446.40
Upside: +5.29%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $64.09
Upside: +9.22%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $2.47
Upside: +61.94%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.26
Upside: +145.40%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $42.95
Upside: +67.64%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $13.15
Upside: +280.23%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.54
Upside: +351.26%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $16.31
Upside: +206.56%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $5.04
Upside: +574.60%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $23.26
Upside: +50.47%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $2.29
Upside: +642.36%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.39
Upside: +376.76%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $33.37
Upside: +169.70%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $40.66
Upside: +195.13%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $22.97
Upside: +148.15%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $50.05
Upside: -26.07%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $53.85
Upside: +85.70%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $5.12
Upside: +271.09%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $61.67
Upside: +58.91%